Abiopharma

🔍 Susan Lior (Executive)

Company: Cerebras Systems Inc. (CBRS)

Report Date: 2026-06-11

Detailed Transactions and Holdings:

• Acquired 13,466,197 shares of Class A Common Stock (Direct)
  Date: 2026-06-11 | Code: C | equity_swap_involved: false | shares_owned_after: 13,466,197.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
• Sold 13,466,197 shares of Class B Common Stock (Derivative)
  Date: 2026-06-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F1, F3, F3, F3, F3

Footnotes:

• F1: Represents shares of Class A common stock that were acquired by the Reporting Person upon voluntary conversion of shares of Class B common stock.
• F2: Consists of (i) 800,358 shares of Class A common stock held by Eclipse Continuity Fund I, L.P. ("Eclipse Continuity Fund"); (ii) 6,548,466 shares of Class A common stock held by Eclipse SPV II, L.P. ("Eclipse SPV II"); (iii) 599,880 shares of Class A common stock held by Eclipse SPV XIII, L.P. ("Eclipse SPV XIII"); and (iv) 5,517,493 shares of Class A common stock held by Eclipse Ventures Fund I, L.P. ("Eclipse Fund," and together with Eclipse Continuity Fund, Eclipse SPV II, and Eclipse SPV XIII, "Eclipse Entities"). The Reporting Person is the sole managing member of the general partner of each of the Eclipse Entities and may be deemed to have voting, investment, and dispositive power with respect to the shares held by such entities.
• F3: Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. On June 11, 2026, the following shares held by the Eclipse Entities were voluntarily converted to Class A common stock: (i) 800,358 shares of Class B common stock held by Eclipse Continuity Fund, (ii) 6,548,466 shares of Class B common stock held by Eclipse SPV II, (iii) 599,880 shares of Class B common stock held by Eclipse SPV XIII, and (iv) 5,517,493 shares of Class B common stock held by Eclipse Fund.